Several tools are available to characterize the disruption of YAP1/TAZ-TEAD binding and its use for cancer treatment, including dominant-negative proteins, peptides that block YAP1-TEAD interactions, and drugs that inhibit TEAD activity. This evidence concerns the gene YAP1 and cancer.